Neuroscience
Meta-Analysis
100%
Dementia Praecox
91%
Major Depressive Disorder
80%
Typical Antipsychotic
35%
Mood Disorder
28%
Placebo
25%
Receptor Gene
24%
Bipolar Disorder
22%
Randomized Controlled Trial
21%
Brain-Derived Neurotrophic Factor
20%
Methamphetamine-Induced Psychosis
18%
Antidepressant
15%
Antipsychotic
14%
Haplotype
14%
Aripiprazole
13%
Negative Syndrome
13%
Fluvoxamine
12%
Bipolar Depression
12%
5-HT6 Receptor
11%
Selective Serotonin Reuptake Inhibitor
11%
Positive Syndrome
11%
Risperidone
11%
Dorsolateral Prefrontal Cortex
10%
Olanzapine
9%
Quetiapine
9%
Alzheimer's Disease
9%
5-HT1A Receptor
8%
Nuclear Receptor NR1D1
8%
Memantine
8%
Lurasidone
8%
Treatment of Schizophrenia
7%
Systematic Review
7%
Cognitive Function
6%
CHRNA4
6%
Suvorexant
6%
Hamilton Rating Scale for Depression
6%
Startle Response
6%
Prokineticin
6%
Nuclear Receptor
6%
Catecholamine
6%
Mood Stabilizer
6%
Circadian Rhythm
5%
Haloperidol
5%
Voxel-Based Morphometry
5%
DNA Polymorphism
5%
Neu Differentiation Factor
5%
Factor X
5%
Lewy Body
5%
Methyltransferase
5%
Mirtazapine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
55%
Typical Antipsychotic
32%
Antipsychotic
32%
Adverse Event
31%
Randomized Controlled Trial
29%
Aripiprazole
25%
Major Depression
22%
Negative Syndrome
20%
Alzheimer's Disease
18%
Disease
17%
Blonanserin
17%
Positive Syndrome
15%
Olanzapine
15%
Quetiapine
15%
Memantine
14%
Bipolar Depression
14%
Remission
14%
Risperidone
14%
Lurasidone
13%
Recurrence Risk
12%
Symptom
11%
Paliperidone
11%
Tolerability
10%
Brexpiprazole
9%
Random Effects Model
8%
Headache
8%
Perospirone
7%
Bipolar Disorder
7%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
7%
Akathisia
6%
Somnolence
6%
Clozapine
6%
Antidepressant
6%
Delirium
5%
Yokukansan
5%
Add on Therapy
5%
Suvorexant
5%
Monotherapy
5%
Depression
5%
Keyphrases
Meta-analysis
42%
Major Depressive Disorder
33%
Systematic Meta-analysis
26%
Schizophrenia
21%
Japanese Population
15%
Gene Disorders
12%
Network Meta-analysis
11%
Intermittent theta Burst Stimulation (iTBS)
11%
Standardized Mean Difference
9%
Randomized Placebo-controlled Trial
9%
Confidence Interval
8%
Adverse Events
8%
Brain-derived Neurotrophic Factor
8%
Alzheimer's Disease
8%
Lurasidone
8%
Non-associated
7%
Placebo
7%
Risk Ratio
7%
Association Study
7%
Japan
7%
Bipolar Depression
6%
Mood Disorders
6%
Tolerability
6%
HF-rTMS
6%
Aripiprazole
6%
Bipolar Disorder
6%
Serotonin 6 Receptor
5%
Serotonin-1A Receptor
5%
Protease-activated Receptor 4 (PAR4)
5%
Receptor Gene
5%
Aripiprazole Once-monthly
5%
Translin
5%
X Gene
5%
SIRT1 Gene
5%
Methamphetamine-induced Psychosis
5%
Memantine
5%
Meta-analysis of Randomized Controlled Trials
5%
Treatment-resistant Depressive Disorder
5%
Newer Antidepressants
5%
Discontinuation Rate
5%
Genotype
5%
Pathophysiology
5%
Pairwise Meta-analysis
5%
Antidepressants
5%
Stimulation Protocol
5%
